[go: up one dir, main page]

NL300324I1 - Op papillomavirus lijkende deeltjes, fusie-eiwitten alsook werkwijze - Google Patents

Op papillomavirus lijkende deeltjes, fusie-eiwitten alsook werkwijze

Info

Publication number
NL300324I1
NL300324I1 NL300324C NL300324C NL300324I1 NL 300324 I1 NL300324 I1 NL 300324I1 NL 300324 C NL300324 C NL 300324C NL 300324 C NL300324 C NL 300324C NL 300324 I1 NL300324 I1 NL 300324I1
Authority
NL
Netherlands
Prior art keywords
particles
proteins
deleted
fusion proteins
vlp
Prior art date
Application number
NL300324C
Other languages
English (en)
Original Assignee
Univ Loyola Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25940851&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300324(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19944435907 external-priority patent/DE4435907C2/de
Priority claimed from DE1995126752 external-priority patent/DE19526752C2/de
Application filed by Univ Loyola Chicago filed Critical Univ Loyola Chicago
Publication of NL300324I1 publication Critical patent/NL300324I1/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NL300324C 1994-10-07 2007-12-14 Op papillomavirus lijkende deeltjes, fusie-eiwitten alsook werkwijze NL300324I1 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19944435907 DE4435907C2 (de) 1994-10-07 1994-10-07 Papillomavirusähnliche Partikel und deren Anwendung
DE1995126752 DE19526752C2 (de) 1995-07-21 1995-07-21 Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln
PCT/EP1995/003974 WO1996011272A2 (de) 1994-10-07 1995-10-09 Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung

Publications (1)

Publication Number Publication Date
NL300324I1 true NL300324I1 (nl) 2008-03-03

Family

ID=25940851

Family Applications (2)

Application Number Title Priority Date Filing Date
NL300324C NL300324I1 (nl) 1994-10-07 2007-12-14 Op papillomavirus lijkende deeltjes, fusie-eiwitten alsook werkwijze
NL300323C NL300323I2 (nl) 1994-10-07 2007-12-14 Op papillomavirus lijkende deeltjes, fusie-eiwitten alsook werkwijze voor de bereiding ervan

Family Applications After (1)

Application Number Title Priority Date Filing Date
NL300323C NL300323I2 (nl) 1994-10-07 2007-12-14 Op papillomavirus lijkende deeltjes, fusie-eiwitten alsook werkwijze voor de bereiding ervan

Country Status (13)

Country Link
US (6) US6066324A (nl)
EP (2) EP1728800A1 (nl)
JP (6) JPH11504801A (nl)
AT (1) ATE325875T1 (nl)
AU (2) AU4270196A (nl)
CA (1) CA2202090C (nl)
DE (3) DE122007000093I1 (nl)
DK (1) DK0809700T3 (nl)
ES (1) ES2264563T3 (nl)
LU (2) LU91401I2 (nl)
NL (2) NL300324I1 (nl)
PT (1) PT809700E (nl)
WO (1) WO1996011272A2 (nl)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164350A1 (en) 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
ES2264563T3 (es) * 1994-10-07 2007-01-01 Loyola University Of Chicago Particulas semejantes al virus del papiloma, proteinas de fusion y procedimiento para su preparacion.
DE69734829D1 (de) 1996-07-17 2006-01-12 Us Health Infektiöse pseudovirale papillomavirus partikel
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
WO1998028003A1 (en) * 1996-12-20 1998-07-02 Merck & Co., Inc. Formulations of recombinant papillomavirus vaccines
WO1999001557A1 (en) * 1997-07-03 1999-01-14 University Of Colorado, University Technology Corporation Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
US7351533B2 (en) * 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
AU2003200653B2 (en) * 1997-10-06 2007-01-18 Loyola University Of Chicago Papilloma virus capsomere vaccine formulations and methods of use
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) * 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US7182947B2 (en) * 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
DE19812940A1 (de) * 1998-03-24 1999-10-07 Medigene Ag Formulierung mit Papillomavirus-spezifischem Protein, seine Herstellung und Verwendung
US6926897B1 (en) * 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
GB9806666D0 (en) * 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
WO2000009157A1 (en) * 1998-08-14 2000-02-24 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
EP1126876B1 (en) 1998-10-16 2007-03-21 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
SE514982C2 (sv) * 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
US20040146531A1 (en) * 1999-09-30 2004-07-29 Active Biotech Ab Virus-like particles devoid of HPV 16 type-specific antibody epitopes as carriers of peptides for introduction into cells
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
WO2002004007A2 (en) * 2000-07-06 2002-01-17 Georgetown University Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
DE60326449D1 (de) * 2002-05-17 2009-04-16 Univ Cape Town Chimere human papilloma virus 16 l1 proteine, welche ein l2 peptid enthalten, damit hergestellte virus-ähnliche partikel und methode zur herstellung der partikel
US20060088909A1 (en) * 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US20080160040A1 (en) * 2004-04-15 2008-07-03 Ghim Shin-Je Plant-produced compositions for treating papillomavirus infection and related methods
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2008082719A2 (en) * 2006-08-30 2008-07-10 University Of Rochester Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
CN101148661B (zh) * 2006-09-18 2013-01-02 中国医学科学院基础医学研究所 人乳头瘤病毒16型外壳蛋白病毒样颗粒及其制备方法和用途
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
BRPI0716959A2 (pt) 2006-09-26 2013-10-29 Infectious Disease Res Inst Composição de vacina contendo adjuvante sintético
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US20100003704A1 (en) 2008-06-13 2010-01-07 Shuling Cheng IN SITU detection of early stages and late stages HPV infection
WO2008115631A2 (en) * 2007-02-08 2008-09-25 University Of Louisville Research Foundation, Inc. Plant-produced compositions for treating papillomavirus infection and related methods
CA2896131C (en) 2007-03-02 2020-04-07 Glaxosmithkline Biologicals S.A. Novel method and compositions
CN101570571B (zh) 2007-04-29 2012-07-11 北京万泰生物药业股份有限公司 截短的人乳头瘤病毒18型l1蛋白
DK2154147T3 (en) 2007-04-29 2015-12-07 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated L1 protein of human papillomavirus 16
CN101343315B (zh) * 2007-05-29 2012-06-13 厦门大学 截短的人乳头瘤病毒6型l1蛋白
US20100260792A1 (en) * 2007-10-22 2010-10-14 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
EP2479187A1 (en) * 2007-11-23 2012-07-25 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein L1 of human papilloma viruses
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
JP2012526286A (ja) 2009-05-07 2012-10-25 オンコヘルス コーポレーション ヒトパピローマウイルス（ｈｐｖ）およびｈｐｖ関連癌の初期段階および後期段階の検出、スクリーニング、および診断のための高度または≧ｃｉｎ２の同定
TWI549688B (zh) 2009-06-05 2016-09-21 美國疾病傳染研究機構 合成的葡萄吡喃糖基脂質佐劑
JP5819851B2 (ja) 2010-01-08 2015-11-24 オンコヘルス コーポレーション Ｈｐｖ関連の癌の治療及びスクリーニングのための細胞に基づいた高処理能力ｈｐｖ免疫アッセイ
US9044420B2 (en) 2011-04-08 2015-06-02 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2012174220A1 (en) * 2011-06-14 2012-12-20 Globeimmune, Inc. Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
US20140127260A1 (en) 2011-06-24 2014-05-08 Ramesh V. Chintala Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
CA2847604A1 (en) 2011-09-08 2013-03-14 Uniqure Ip B.V. Removal of contaminating viruses from aav preparations
SMT201900324T1 (it) 2012-02-07 2019-07-11 Infectious Disease Res Inst Formulazione migliorata di adiuvante comprendenti agonisti tlr4 e metodi per il loro uso
US20150110824A1 (en) 2012-03-18 2015-04-23 Glaxosmithkline Biologicals, Sa Method of vaccination against human papillomavirus
EP3388835B1 (en) 2012-05-16 2020-04-01 Immune Design Corp. Vaccines for hsv-2
BR112015025709A2 (pt) 2013-04-18 2017-07-18 Immune Design Corp monoterapia com gla para uso em tratamento de câncer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN104231060B (zh) * 2013-06-05 2018-05-15 厦门大学 人乳头瘤病毒l1l2衣壳蛋白相互作用位点及其应用
EP3915579A1 (en) 2013-12-31 2021-12-01 Infectious Disease Research Institute Single vial vaccine formulations
WO2017200957A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
US11344619B2 (en) 2016-05-16 2022-05-31 Access To Advanced Health Institute Formulation containing TLR agonist and methods of use
MX393217B (es) 2016-06-01 2025-03-11 Infectious Disease Res Inst Particulas de nanoalumbre que contienen un agente de dimensionamiento
EP3638207B1 (en) 2017-06-15 2024-12-18 Access to Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof
CA3078223A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
EP3911663A4 (en) * 2018-12-28 2022-09-28 The Board Of Trustees Of The Leland Stanford Junior University GENETICALLY MODIFIED HEPATITIS B NUCLEUS POLYPEPTIDE
JP2022532944A (ja) 2019-05-25 2022-07-20 アクセス ツー アドバンスト ヘルス インスティチュート アジュバントワクチンエマルジョンを噴霧乾燥するための組成物および方法
CN114127099B (zh) * 2019-07-19 2024-04-19 神州细胞工程有限公司 嵌合的人乳头瘤病毒6型l1蛋白
HRP20250701T1 (hr) * 2019-07-19 2025-09-12 Sinocelltech Ltd Himerni protein papiloma virusa l1
CA3147849A1 (en) 2019-07-19 2021-01-28 Sinocelltech Ltd. Polyvalent immunogenicity composition for human papillomavirus
WO2021013063A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒16型l1蛋白
WO2021013079A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒56型l1蛋白
CN115103687A (zh) 2020-02-14 2022-09-23 默沙东有限公司 Hpv疫苗
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
CN114539363B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种c端改造的人乳头瘤病毒11型l1蛋白及其用途
CN114539365B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种改造的人乳头瘤病毒52型l1蛋白及其用途
MX2023009456A (es) 2021-02-11 2023-08-28 Glaxosmithkline Biologicals Sa Preparacion de la vacuna contra el vph.
EP4359010A1 (en) 2021-06-21 2024-05-01 uniQure biopharma B.V. Improved lysis procedures
WO2023014853A1 (en) 2021-08-06 2023-02-09 Merck Sharp & Dohme Llc Hpv vaccine
TW202315602A (zh) 2021-08-19 2023-04-16 美商默沙東有限責任公司 新穎熱穩定脂質奈米粒子及其使用方法
AU2023336224A1 (en) 2022-09-09 2025-03-27 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
AR132886A1 (es) 2023-06-09 2025-08-06 Merck Sharp & Dohme Llc Composiciones adyuvantes en nanoemulsión para vacunas contra el papilomavirus humano

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
WO1993002184A1 (en) * 1991-07-19 1993-02-04 The University Of Queensland Papilloma virus vaccine
GB9207701D0 (en) 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
CA2118026A1 (en) * 1992-04-14 1993-10-28 Guy T. Layton Induction of ctl responses
DE122007000097I1 (de) 1992-06-25 2008-03-27 Papillomavirus vakzine
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
DE69435331D1 (de) * 1993-03-09 2011-02-03 Univ Rochester Herstellung von menschlichen papillomavirus HBV-11 Kapsidprotein L1 und Virus-ähnliche Partikeln
ES2264563T3 (es) * 1994-10-07 2007-01-01 Loyola University Of Chicago Particulas semejantes al virus del papiloma, proteinas de fusion y procedimiento para su preparacion.
WO1996026277A1 (en) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5874089A (en) * 1995-10-02 1999-02-23 Georgetown University School Of Medicine Protecting against canine oral papillomavirus (copy)
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use

Also Published As

Publication number Publication date
US6599508B1 (en) 2003-07-29
AU760615B2 (en) 2003-05-22
US7416732B2 (en) 2008-08-26
DE122007000093I1 (de) 2008-03-27
LU91390I2 (fr) 2008-02-14
NL300323I1 (nl) 2008-03-03
ATE325875T1 (de) 2006-06-15
WO1996011272A2 (de) 1996-04-18
JP2009102327A (ja) 2009-05-14
EP0809700B1 (de) 2006-05-10
LU91401I2 (fr) 2008-02-14
JP2015037430A (ja) 2015-02-26
US6361778B1 (en) 2002-03-26
DK0809700T3 (da) 2006-09-18
US20040202679A1 (en) 2004-10-14
EP0809700A1 (de) 1997-12-03
US6066324A (en) 2000-05-23
US20110015376A1 (en) 2011-01-20
JP2012010713A (ja) 2012-01-19
JP2013213034A (ja) 2013-10-17
CA2202090A1 (en) 1996-04-18
ES2264563T3 (es) 2007-01-01
JP5794747B2 (ja) 2015-10-14
EP1728800A1 (de) 2006-12-06
JP2005270111A (ja) 2005-10-06
AU1010600A (en) 2000-03-16
WO1996011272A3 (de) 1996-09-26
NL300323I2 (nl) 2010-03-01
CA2202090C (en) 2012-04-17
JPH11504801A (ja) 1999-05-11
PT809700E (pt) 2006-09-29
US20060153864A1 (en) 2006-07-13
DE59511047D1 (de) 2006-06-14
DE122007000092I1 (de) 2008-03-27
AU4270196A (en) 1996-05-02

Similar Documents

Publication Publication Date Title
NL300323I1 (nl) Op papillomavirus lijkende deeltjes, fusie-eiwitten alsook werkwijze
DE122011100018I1 (de) Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen.
DE69535018D1 (de) Papillomavirus vakzine
LU91386I2 (fr) CERVARIX - Particule similaire au virus HPV18
DK0750669T3 (da) Modificeret papillomavirus-L2-protein og VLP'er dannet derudfra